A U.S. unit of India’s Glenmark Pharmaceuticals Ltd. was charged with conspiring with competitors to raise prices for generic drugs, the Justice Department said on Tuesday.
The Glenmark subsidiary colluded with other drug companies to stop competing and artificially raise the prices of medicines, the department said in a statement.
The company is the fifth to be charged in a years-long investigation into price-fixing by generic-drug companies. Those case were settled with deferred prosecution agreements and criminal fines. The industry is also fighting lawsuits filed by state attorneys general.
Earlier: Novartis Unit Accused of ‘Massive Fraud’ in State Lawsuit